Health Care • Biotechnology: Pharmaceutical Preparations
$273.20 ▼ -2.00
(-0.73%)
MKT CAP: $662.49B • VOL: 8.97M
52W L $185 52W H $282
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$229
MEDIAN
$306
MEAN
$311
HIGH
$372
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE JNJ TAPE
JNJ // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $330.57 | $314.18 | 2025-02-14 | $248.61 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $344.23 | $322.38 | 2025-02-06 | $256.81 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $311.45 | $300.52 | 2025-01-29 | $262.27 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $278.66 | — | 2025-01-17 | $267.74 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $240.42 | $259.54 | 2025-01-09 | $243.15 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $325.11 | $284.13 | 2024-12-18 | $237.68 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $265.00 | $275.93 | 2024-12-04 | $254.08 | -4.3% | 48% | C |